CA2484374A1 - Medical products comprising a haemocompatible coating, production and use thereof - Google Patents

Medical products comprising a haemocompatible coating, production and use thereof Download PDF

Info

Publication number
CA2484374A1
CA2484374A1 CA002484374A CA2484374A CA2484374A1 CA 2484374 A1 CA2484374 A1 CA 2484374A1 CA 002484374 A CA002484374 A CA 002484374A CA 2484374 A CA2484374 A CA 2484374A CA 2484374 A1 CA2484374 A1 CA 2484374A1
Authority
CA
Canada
Prior art keywords
layer
poly
medical device
biostable
biodegradable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002484374A
Other languages
French (fr)
Other versions
CA2484374C (en
Inventor
Roland Horres
Marita Katharina Linssen
Michael Hoffmann
Volker Faust
Erika Hoffmann
Donato Di Biase
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hemoteq AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10221055A external-priority patent/DE10221055B4/en
Application filed by Individual filed Critical Individual
Publication of CA2484374A1 publication Critical patent/CA2484374A1/en
Application granted granted Critical
Publication of CA2484374C publication Critical patent/CA2484374C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
    • A61L33/06—Use of macromolecular materials
    • A61L33/08—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/10—Heparin; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D105/00—Coating compositions based on polysaccharides or on their derivatives, not provided for in groups C09D101/00 or C09D103/00
    • C09D105/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention relates to the use of polysaccharides containing the sugar structural element N-acylglucosamine for producing haemocompatible surfaces, in addition to methods for coating surfaces in a haemocompatible manner with said polysaccharides, the latter constituting the common biosynthetic precursor substances of heparin and heparan sulphates. The invention also relates to coated medical products, in particular stents, which contain paclitaxel as an antiproliferative active ingredient, in addition to the use of said stents for preventing restenosis.

Claims (35)

1. Medical device, wherein at least one part of the surface of the medical device is coated directly or via at least one interjacent biostable and/or biodegradable layer with a hemocompatible layer comprising at least one compound of the formula 1 wherein n represents an integer between 4 and 1050, Y represents a residue -CHO, -COCH3, -COC2H5, -COC3H7, -COC4H9, -COC5H11, -COCH(CH3)2, -COCH2CH(CH3)2, -COCH(CH3)C2H5, -COC(CH3)3, -CH2COO-, -C2H4COO-, -C3H6COO-, -C4H8COO-, as well as salts of these compounds, and on, in and/or under the hemocompatible layer the active agent paclitaxel is present.
2. Medical device according to claim 1, wherein Y represents the residue -CHO, -COCH3, -COC2H5, -COC3H7, as well as salts of these compounds.
3. Medical device according to claim 2, wherein Y is -COCH3.
4. Medical device according to one of the previous claims, wherein the hemocompatible layer is directly placed on the surface of the medical device and onto said hemocompatible layer paclitaxel as well as mixtures of these active agents are deposited.
5. Medical device according to one of the previous claims, wherein under the hemocompatible layer or between two hemocompatible layers at least one biostable and/or biodegradable layer is present.
6. Medical device according to one of the previous claims, wherein the hemocompatible layer is coated completely or/and incompletely with at least one additional, above lying biostable and/or biodegradable layer.
7. Medical device according to one of the previous claims, in which at least one active agent layer of paclitaxel is present between the biostable and the hemocompatible layer.
8. Medical device according to one of the previous claims, in which paclitaxel is bound covalently and/or adhesively in and/or on the hemocompatible layer and/or the biostable and/or the biodegradable layer.
9. Medical device according to one of the previous claims, characterised in, that as biodegradable substances for the biodegradable layer polyvalerolactones, poly-.epsilon.-decalactones, polylactonic acid, polyglycolic acid, polylactides, polyglycolides, copolymers of the polylactides and polyglycolides, poly-.epsilon.-caprolactone, polyhydroxybutanoic acid, polyhydroxybutyrates, polyhydroxyvalerates, polyhydroxybutyrate-co-valerates, poly(1,4-dioxane-2,3-diones), poly(1,3-dioxane-2-one), poly-para-dioxanones, polyanhydrides as polymaleic anhydrides, polyhydroxymethacrylates, fibrin, polycyanoacrylates, polycaprolactonedimethylacrylates, poly-b-maleic acid, polycaprolactonebutyl-acrylates, multiblock polymers as e.g. from oligocaprolactonedioles and oligodioxanonedioles, polyetherester multiblock polymers as e.g. PEG and poly(butyleneterephtalates), polypivotolactones, polyglycolic acid trimethyl-carbonates, polycaprolactone-glycolides, poly(g-ethylglutamate), poly(DTH-iminocarbonate), poly(DTE-co-DT-carbonate), poly(bisphenol-A-iminocarbonate), polyorthoesters, polyglycolic acid trimethyl-carbonates, polytrimethylcarbonates, polyiminocarbonates, poly(N-vinyl)-pyrrolidone, polyvinylalcoholes, polyesteramides, glycolated polyesters, polyphosphoesters, polyphosphazenes, poly[p-carboxyphenoxy)propane], polyhydroxypentane acid, polyanhydrides, polyethyleneoxide-propyleneoxide, soft polyurethanes, polyurethanes with amino acid rests in the backbone, polyetheresters as polyethyleneoxide, polyalkeneoxalates, polyorthoesters as well as their copolymers, lipids, carrageenans, fibrinogen, starch, collagen, protein based polymers, polyamino acids, synthetic polyamino acids, zein, modified zein, polyhydroxyalkanoates, pectic acid, actinic acid, modified and non modified fibrin and casein, carboxymethylsulphate, albumin, moreover hyaluronic acid, chitosane and its derivatives, heparansulphates and its derivatives, heparin, chondroitinsulphate, dextran, b-cyclodextrins, copolymers with PEG and polypropyleneglycol, gummi arabicum, guar, gelatine, collagen, collagen-N-Hydroxysuccinimide, lipids, phospholipids, modifications and copolymers and/or mixtures of afore mentioned substances are used.
10. Medical device according to one of the previous claims, characterised in, that as biostable substances for the biostable layer polyacrylic acid and polyacrylates as polymethylmethacrylate, polybutylmethacrylate, polyacrylamide, polyacrylonitriles, polyamides, polyetheramides, polyethylenamine, polyimides, polycarbonates, polycarbourethanes, polyvinylketones, polyvinylhalogenides, polyvinylidenhalogenides, polyvinylethers, polyisobutylenes, polyvinylaromates, polyvinylesters, polyvinylpyrollidones, polyoxymethylenes, polytetramethyleneoxide, polyethylene, polypropylene, polytetrafluoroethylene, polyurethanes, polyetherurethanes, silicone-polyetherurethanes, silicone-polyurethanes, silicone-polycarbonate-urethanes, polyolefine elastomeres, polyisobutylenes, EPDM gums, fluorosilicones, carboxymethylchitosanes, polyaryletheretherketones, polyetheretherketones, polyethylenterephthalate, polyvalerates, carboxymethylcellulose, cellulose, rayon, rayontriacetates, cellulosenitrates, celluloseacetates, hydroxyethylcellulose, cellulosebutyrates, celluloseacetatebutyrates, ethylvinylacetate copolymers, polysulphones, epoxy resins, ABS resins, EPDM gums, silicones as polysiloxanes, polydimethylsiloxanes, polyvinylhalogenes and copolymers, celluloseethers, cellulosetriacetates, chitosanes and copolymers and/or mixtures of these substances are used.
11. Medical device according to one of the previous claims, whereas instead of the active agent paclitaxel one of the following active agents is used:
simvastatin, 2-methylthiazolidine-2,4-dicarboxylic acid and the correspondent sodium salt, macrocyclic suboxide (MCS), derivatives of MCS, activated protein C (aPC), PETN, trapidil, .beta.-estradiol as well as mixtures of these active agents or mixtures of one of these active agents with paclitaxel.
12. Medical device according to one of the previous claims, characterised in, that the medical device comprises prostheses, organs, vessels, aortas, heart valves, tubes, organ spareparts, implants, fibers, hollow fibers, stents, hollow needles, syringes, membranes, tinned goods, blood containers, titrimetric plates, pacemakers, adsorbing media, chromatography media, chromatography columns, dialyzers, connexion parts, sensors, valves, centrifugal chambers, recuperators, endoscopes, filters, pump chambers.
13. Medical device according to claim 12, characterised in, that the medical device is a stent.
14. Stents according to claim 13, wherein the polymer is deposited in amounts between 0.01 mg to 3 mg / layer, preferred between 0.20 mg to 1 mg and especially preferred between 0.2 mg to 0.5 mg / layer.
15. Stent according to claim 13 or 14, characterised in, that the active agent is used in a pharmaceutically active concentration of 0.001 - 10 mg per cm2 stent surface and per layer.
16. Use of the stent according to one of the claims 13 - 15 for the prevention or reduction of restenosis.
17. Use of the stent according to one of the claims 13 - 16 for continuous release of paclitaxel, simvastatin, , 2-methylthiazolidine-2,4-dicarboxylic sodium salt, macrocyclic suboxide (MCS), derivatives of MCS, activated protein C (aPC), PETN, trapidil and/or .beta.-estradiol.
18. Use of the medical devices according to one of the claims 1 - 15 for the direct contact with blood.
19. Use of the medical devices according to one of the claims 1 - 15 for prevention or reduction of the unspecific adhesion and/or deposition of proteins on the coated surfaces of the medical devices.
20. Use according to claim 18 or 19, characterised in, that the hemocompatibly coated surface of the medical device is a surface of micro-titer plates or other carrier media for detection processes.
21. Use according to claim 18 or 19, characterised in, that the hemocompatibly coated surface of the medical device is the surface of adsorber media or chromatography media.
22. Method for the hemocompatible coating of biological and/or artificial surfaces of medical devices comprising the following steps:
a) providing a surface of a medical device and b) deposition of at least one compound of the general formula 1 according to claim 1 as hemocompatible layer on this surface and/or b') deposition of a biostable and/or biodegradable layer on the surface of the medical device or the hemocompatible layer.
23. Method according to claim 22, wherein the hemocompatible layer or the biostable and/or biodegradable layer is coated via dipping or spraying method with at least one biodegradable and/or biostabile layer which conspires paclitaxel covalently and/or adhesively bound.
24. Method according to claim 22 or 23 comprising the further step c):
c. deposition of paclitaxel in and/or on the hemocompatible layer or the biostable and/or biodegradable layer.
25. Method according to claim 24, wherein paclitaxel is implemented and/or deposited via dipping or spraying methods on and/or in the hemocompatible layer or the biostable and/or biodegredable layer and/or is bound via covalent and/or adhesive coupling to the hemocompatible layer or the biostable and/or biodegradable layer.
26. Method according to one of the claims 22 - 25, comprising the further step d) or d'):
d. deposition of at least one biodegradable layer and/or at least one biostable and/or biodegradable layer on the hemocompatible layer or the layer of paclitaxel respectively, or d') deposition of at least one compound of the general formula 1 according to claim 1 as hemocompatible layer on the biostable and/or biodegradable layer or the layer of paclitaxel.
27. Method according to one of the claims 22 - 26, comprising the further step e.):
e. deposition of paclitaxel in and/or on the at least one biodegradable and/or biostable layer or the hemocompatible layer.
28. Method according to claim 27, wherein paclitaxel is deposited and/or implemented via dipping or spraying methods on and/or in the at least one biodegradable and/or biostable layer or the hemocompatible layer and/or is bound via covalent and/or adhesive coupling to the at least one biodegradable and/or biostable layer or the hemocompatible layer.
29. Method according to one of the claims 22 - 28, wherein the biostable and/or biodegradable layer is covalently and/or adhesively bound on the surface of the medical device and the hemocompatible layer is covalently bound to the biostable and/or biodegradable layer and covers it completely or incompletely.
30. Method according to one of the claims 22 - 29, characterised in, that the hemocompatible layer comprises heparin of native origin of regioselectively synthesised derivatives of different sulphation coefficients and acylation coefficients in the molecular weight range of the pentasaccharide, which is responsible for the antithrombotic activity, up to the standard molecular weight of the purchasable heparin of 13 kD, heparansulphate and its derivatives, oligo- and polysaccharides of the erythrocytic glycocalix, desulphated and N-reacetylated heparin, N-carboxymethylated and/or partially N-acetylated chitosan as well as mixtures of these substances.
31. Method according to one of the claims 22 - 30, characterised in, that as biodegradable substances for the biodegradable layer polyvalerolactones, poly-.epsilon.-decalactones, polylactonic acid, polyglycolic acid, polylactides, polyglycolides, copolymers of the polylactides and polyglycolides, poly-.epsilon.-caprolactone, polyhydroxybutanoic acid, polyhydroxybutyrates, polyhydroxyvalerates, polyhydroxybutyrate-co-valerates, poly(1,4-dioxane-2,3-diones), poly(1,3-dioxane-2-one), poly-para-dioxanones, polyanhydrides as polymaleic anhydrides, polyhydroxymethacrylates, fibrin, polycyanoacrylates, polycaprolactonedimethylacrylates, poly-b-maleic acid, polycaprolactonebutyl-acrylates, multiblock polymers as e.g.. from oligocaprolactonedioles and oligodioxanonedioles, polyetherester multiblock polymers as .e.g. PEG and poly(butyleneterephtalates), polypivotolactones, polyglycolic acid trimethyl-carbonates, polycaprolactone-glycolides, poly(g-ethylglutamate), poly(DTH-iminocarbonate), poly(DTE-co-DT-carbonate), poly(bisphenol-A-iminocarbonate), polyorthoesters, polyglycolic acid trimethyl-carbonates, polytrimethylcarbonates, polyiminocarbonates, poly(N-vinyl)-pyrrolidone, polyvinylalcoholes, polyesteramides, glycolated polyesters, polyphosphoesters, polyphosphazenes, poly[p-carboxyphenoxy)propane], polyhydroxypentane acid, polyanhydrides, polyethyleneoxide-propyleneoxide, soft polyurethanes, polyurethanes with amino acid rests in the backbone, polyetheresters as polyethyleneoxide, polyalkeneoxalates, polyorthoesters as well as their copolymers, lipides, carrageenanes, fibrinogen, starch, collagen, protein based polymers, polyamino acids, synthetic polyamino acids, zein, modified zein, polyhydroxyalkanoates, pectic acid, actinic acid, modified and non modified fibrin and casein, carboxymethylsulphate, albumin, moreover hyaluronic acid, chitosane and its derivatives, heparansulphates and its derivatives, heparin, chondroitinsulphate, dextran, .beta.-cyclodextrins, copolymers with PEG and polypropyleneglycol, gummi arabicum, guar, gelatine, collagen, collagen-N-Hydroxysuccinimide, lipids, phospholipids, modifications and copolymers and/or mixtures of afore mentioned substances are used.
32. Method according to one the claims 22 - 31, characterised in, that as biostable substances for the biostable layer polyacrylic acid and polyacrylates as polymethylmethacrylate, polybutylmethacrylate, polyacrylamide, polyacrylonitriles, polyamides, polyetheramides, polyethylenamine, polyimides, polycarbonates, polycarbourethanes, polyvinylketones, polyvinylhalogenides, polyvinylidenhalogenides, polyvinylethers, polyisobutylenes, polyvinylaromates, polyvinylesters, polyvinylpyrollidones, polyoxymethylenes, polytetramethyleneoxide, polyethylene, polypropylene, polytetrafluoroethylene, polyurethanes, polyetherurethanes, silicone-polyetherurethanes, silicone-polyurethanes, silicone-polycarbonate-urethanes, polyolefine elastomeres, polyisobutylenes, EPDM gums, fluorosilicones, carboxymethylchitosanes, polyaryletheretherketones, polyetheretherketones, polyethylenterephthalate, polyvalerates, carboxymethylcellulose, cellulose, rayon, rayontriacetates, cellulosenitrates, celluloseacetates, hydroxyethylcellulose, cellulosebutyrates, celluloseacetatebutyrates, ethylvinylacetate copolymers, polysulphones, epoxy resins, ABS resins, EPDM gums, silicones as polysiloxanes, polydimethylsiloxanes, polyvinylhalogenes and copolymers, celluloseethers, cellulosetriacetates, chitosanes and copolymers and/or mixtures of these substances are used.
33. Method according to one of the claims 22 - 32, characterised in, that the deposition of the polysaccharides of the formula 1 according to claim 1 is achieved via hydrophobic interactions, van der Waals forces, electrostatic interactions, hydrogen bonds, ionic interactions, cross-linking and/or covalent bonding.
34. Method according to one of the claims 22 - 33, wherein instead of the active agent paclitaxel one of the following active agents is used: simvastatin, 2-methylthiazolidine-2,4-dicarboxylic sodium salt, macrocyclic suboxide (MCS), derivatives of MCS, activated protein C (aPC), PETN, trapidil, .beta.-estradiol as well as mixtures of these active agents or mixtures of one of these active agents with paclitaxel.
35. Medical device available by one method according to one of the claims 22 -34.
CA2484374A 2002-05-09 2003-04-15 Medical products comprising a haemocompatible coating, production and use thereof Expired - Fee Related CA2484374C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US37867602P 2002-05-09 2002-05-09
US60/378,676 2002-05-09
DE10221055A DE10221055B4 (en) 2002-05-10 2002-05-10 Compounds for hemocompatible coating of surfaces, process for their preparation and their use
DE10221055.1 2002-05-10
PCT/DE2003/001254 WO2003094991A1 (en) 2002-05-09 2003-04-15 Medical products comprising a haemocompatible coating, production and use thereof

Publications (2)

Publication Number Publication Date
CA2484374A1 true CA2484374A1 (en) 2003-11-20
CA2484374C CA2484374C (en) 2011-05-17

Family

ID=29421502

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2484374A Expired - Fee Related CA2484374C (en) 2002-05-09 2003-04-15 Medical products comprising a haemocompatible coating, production and use thereof
CA2484269A Expired - Fee Related CA2484269C (en) 2002-05-09 2003-04-15 Compounds and method for coating surfaces in a haemocompatible manner

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2484269A Expired - Fee Related CA2484269C (en) 2002-05-09 2003-04-15 Compounds and method for coating surfaces in a haemocompatible manner

Country Status (20)

Country Link
US (3) US20050176678A1 (en)
EP (2) EP1501565B1 (en)
JP (3) JP4208830B2 (en)
CN (2) CN1665554B (en)
AT (2) ATE404232T1 (en)
AU (2) AU2003240391B8 (en)
BR (2) BR0310008A (en)
CA (2) CA2484374C (en)
DE (4) DE10393059D2 (en)
DK (2) DK1501566T3 (en)
EA (1) EA009092B1 (en)
ES (2) ES2321082T3 (en)
IL (3) IL164947A0 (en)
MX (2) MXPA04011112A (en)
NZ (2) NZ536330A (en)
PL (2) PL208277B1 (en)
PT (2) PT1501566E (en)
SI (1) SI1501566T1 (en)
WO (2) WO2003094991A1 (en)
ZA (2) ZA200408757B (en)

Families Citing this family (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8527026B2 (en) 1997-03-04 2013-09-03 Dexcom, Inc. Device and method for determining analyte levels
US6001067A (en) 1997-03-04 1999-12-14 Shults; Mark C. Device and method for determining analyte levels
US20030032874A1 (en) 2001-07-27 2003-02-13 Dexcom, Inc. Sensor head for use with implantable devices
US7828728B2 (en) 2003-07-25 2010-11-09 Dexcom, Inc. Analyte sensor
US8364229B2 (en) 2003-07-25 2013-01-29 Dexcom, Inc. Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise
US7613491B2 (en) 2002-05-22 2009-11-03 Dexcom, Inc. Silicone based membranes for use in implantable glucose sensors
WO2003094991A1 (en) * 2002-05-09 2003-11-20 Hemoteq Gmbh Medical products comprising a haemocompatible coating, production and use thereof
US7226978B2 (en) 2002-05-22 2007-06-05 Dexcom, Inc. Techniques to improve polyurethane membranes for implantable glucose sensors
WO2004010900A1 (en) * 2002-07-25 2004-02-05 Avantec Vascular Corporation Devices delivering therapeutic agents and methods regarding the same
KR20050086648A (en) * 2002-11-15 2005-08-30 노파르티스 아게 Drug delivery system
FR2847474B1 (en) * 2002-11-25 2006-03-24 Inst Rech Developpement Ird USE OF CANTHIN-6-ONE, PLANT EXTRACTS CONTAINING THEM AND ITS DERIVATIVES IN THE TREATMENT OF CHAGAS DISEASE
US7758881B2 (en) * 2004-06-30 2010-07-20 Advanced Cardiovascular Systems, Inc. Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
AR043504A1 (en) * 2003-03-17 2005-08-03 Novartis Ag PHARMACEUTICAL COMPOSITIONS THAT INCLUDE RAPAMYCIN FOR THE TREATMENT OF INFLAMMATORY DISEASES
DE10328815A1 (en) * 2003-06-21 2005-01-05 Biotronik Meß- und Therapiegeräte GmbH & Co. Ingenieurbüro Berlin Coating system for implants to increase tissue compatibility
US9763609B2 (en) 2003-07-25 2017-09-19 Dexcom, Inc. Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise
US7074307B2 (en) 2003-07-25 2006-07-11 Dexcom, Inc. Electrode systems for electrochemical sensors
JP4708342B2 (en) 2003-07-25 2011-06-22 デックスコム・インコーポレーテッド Oxygen augmentation membrane system for use in implantable devices
WO2007120442A2 (en) 2003-07-25 2007-10-25 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US7920906B2 (en) 2005-03-10 2011-04-05 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US7488343B2 (en) 2003-09-16 2009-02-10 Boston Scientific Scimed, Inc. Medical devices
US20050129731A1 (en) * 2003-11-03 2005-06-16 Roland Horres Biocompatible, biostable coating of medical surfaces
EP1682196A2 (en) * 2003-11-10 2006-07-26 Angiotech International Ag Medical implants and anti-scarring agents
US9247900B2 (en) 2004-07-13 2016-02-02 Dexcom, Inc. Analyte sensor
US8423114B2 (en) 2006-10-04 2013-04-16 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
EP1711790B1 (en) 2003-12-05 2010-09-08 DexCom, Inc. Calibration techniques for a continuous analyte sensor
US11633133B2 (en) 2003-12-05 2023-04-25 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US8137397B2 (en) 2004-02-26 2012-03-20 Boston Scientific Scimed, Inc. Medical devices
US20050214339A1 (en) 2004-03-29 2005-09-29 Yiwen Tang Biologically degradable compositions for medical applications
DE102004021658A1 (en) * 2004-05-03 2005-12-01 Rudy Dr. Susilo Anticancer product comprises 2-methylthiazolidine-2,4-dicarboxylic acid and an antiangiogenic, cytotoxic or cytostatic compound
US8277713B2 (en) 2004-05-03 2012-10-02 Dexcom, Inc. Implantable analyte sensor
US7803182B2 (en) * 2004-05-28 2010-09-28 Cordis Corporation Biodegradable vascular device with buffering agent
US7670282B2 (en) 2004-06-14 2010-03-02 Pneumrx, Inc. Lung access device
US20050281740A1 (en) * 2004-06-16 2005-12-22 Glen Gong Imaging damaged lung tissue
US20050281799A1 (en) * 2004-06-16 2005-12-22 Glen Gong Targeting damaged lung tissue using compositions
US20050281739A1 (en) * 2004-06-16 2005-12-22 Glen Gong Imaging damaged lung tissue using compositions
US7678767B2 (en) 2004-06-16 2010-03-16 Pneumrx, Inc. Glue compositions for lung volume reduction
US7608579B2 (en) * 2004-06-16 2009-10-27 Pneumrx, Inc. Lung volume reduction using glue compositions
US20050281798A1 (en) * 2004-06-16 2005-12-22 Glen Gong Targeting sites of damaged lung tissue using composition
US8709469B2 (en) 2004-06-30 2014-04-29 Abbott Cardiovascular Systems Inc. Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
US7766938B2 (en) 2004-07-08 2010-08-03 Pneumrx, Inc. Pleural effusion treatment device, method and material
US7766891B2 (en) 2004-07-08 2010-08-03 Pneumrx, Inc. Lung device with sealing features
US7654956B2 (en) 2004-07-13 2010-02-02 Dexcom, Inc. Transcutaneous analyte sensor
WO2006127694A2 (en) 2004-07-13 2006-11-30 Dexcom, Inc. Analyte sensor
EP1814544A4 (en) * 2004-11-05 2009-12-02 Cephalon Inc Cancer treatments
JP4874259B2 (en) 2004-11-23 2012-02-15 ヌームアールエックス・インコーポレーテッド Steerable device for accessing the target site
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
CN101146514B (en) * 2005-02-18 2013-03-27 阿布拉西斯生物科学公司 Drugs with improved hydrophobicity for incorporation in medical devices
US20060204546A1 (en) * 2005-03-14 2006-09-14 Conor Medsystems, Inc. Methods and systems for delivering immunosuppressant and anti-inflammatory agents from a stent
US8744546B2 (en) 2005-05-05 2014-06-03 Dexcom, Inc. Cellulosic-based resistance domain for an analyte sensor
JP5026004B2 (en) * 2005-06-28 2012-09-12 江崎グリコ株式会社 Titanium implant material containing phosphorylated saccharide
GB0515003D0 (en) * 2005-07-21 2005-08-31 Univ Aston Medical devices and coatings therefor
DE102005040211B4 (en) 2005-08-16 2010-02-11 Maquet Cardiopulmonary Ag Use of nonionic esters in a coating for blood contacting surfaces and medical device
US20070048350A1 (en) * 2005-08-31 2007-03-01 Robert Falotico Antithrombotic coating for drug eluting medical devices
CN104013996B (en) * 2005-11-15 2018-02-02 奥巴斯尼茨医学公司 The drug eluting implantable medical device of progenitor endothelial cell capturing
US20070142905A1 (en) * 2005-12-16 2007-06-21 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
US20070207183A1 (en) * 2006-01-05 2007-09-06 Med Institute, Inc. Zein coated medical device
US8840660B2 (en) 2006-01-05 2014-09-23 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US20070212388A1 (en) * 2006-03-08 2007-09-13 Sahajanand Medical Technologies Pvt. Ltd. Compositions comprising porous articles and uses in implantable medical devices
US9402633B2 (en) 2006-03-13 2016-08-02 Pneumrx, Inc. Torque alleviating intra-airway lung volume reduction compressive implant structures
US8888800B2 (en) 2006-03-13 2014-11-18 Pneumrx, Inc. Lung volume reduction devices, methods, and systems
US8157837B2 (en) 2006-03-13 2012-04-17 Pneumrx, Inc. Minimally invasive lung volume reduction device and method
JP2007244601A (en) * 2006-03-15 2007-09-27 Kanazawa Univ Pad for cardiac muscle
EP2019657B1 (en) 2006-04-26 2015-05-27 Micell Technologies, Inc. Coatings containing multiple drugs
US20070254002A1 (en) * 2006-04-26 2007-11-01 Sheng-Qian Wu Biocompatible devices coated with activated protein C
CA2775940A1 (en) * 2006-07-03 2008-01-10 Hemoteq Ag Catheter balloon with polymeric coating
EP1887355B1 (en) * 2006-08-02 2017-09-27 F. Hoffmann-La Roche AG Coating method for a microfluidic system.
WO2008086490A2 (en) * 2007-01-11 2008-07-17 Robert Lamar Bjork, Jr Multiple drug-eluting coronary artery stent for percutaneous coronary artery intervention
US9359718B2 (en) * 2007-01-16 2016-06-07 Dainichiseika Color & Chemicals Mfg. Co., Ltd. Aqueous solution composition
CA2743022C (en) 2007-01-21 2012-10-09 Hemoteq Ag Methods for coating catheter balloons with a defined quantity of active agent
CA2682291C (en) * 2007-04-19 2013-08-13 Medovent Gmbh Device made at least partially of n-acetylchitosan with controlled biodissolution
JP2010526625A (en) * 2007-05-15 2010-08-05 カメレオン バイオサーフェセズ リミテッド Polymer coating on medical devices
US20200037874A1 (en) 2007-05-18 2020-02-06 Dexcom, Inc. Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise
US20100161021A1 (en) * 2007-06-07 2010-06-24 National University Corporation Kanazawa University Myocardial pad
US9192697B2 (en) 2007-07-03 2015-11-24 Hemoteq Ag Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis
US8070798B2 (en) 2007-07-20 2011-12-06 Josiah Wilcox Drug eluting medical device and method
EP2258414A3 (en) 2007-09-04 2014-08-27 Japan Stent Technology Co., Ltd. Sustained drug-releasing stent
US20090092664A1 (en) * 2007-10-08 2009-04-09 University Of Kentucky Research Foundation Polymer-metal chelator conjugates and uses thereof
WO2009049426A1 (en) * 2007-10-19 2009-04-23 Interface Biologics Inc. Self-eliminating coatings
EP2214747A2 (en) * 2007-11-20 2010-08-11 Cook Incorporated Controlled drug delivery using a zein layer modified with levulinic acid
ES2386231T3 (en) * 2007-11-30 2012-08-14 Universiteit Maastricht Diagnostic and therapeutic tool for diseases that alter vascular function
US9717896B2 (en) 2007-12-18 2017-08-01 Gearbox, Llc Treatment indications informed by a priori implant information
US8636670B2 (en) 2008-05-13 2014-01-28 The Invention Science Fund I, Llc Circulatory monitoring systems and methods
US20090287120A1 (en) 2007-12-18 2009-11-19 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Circulatory monitoring systems and methods
CN101234217B (en) * 2008-03-07 2013-12-18 苏州盖依亚生物医药有限公司 Functional targeting therapeutic degradable biological bracket and use thereof
AR072777A1 (en) 2008-03-26 2010-09-22 Cephalon Inc SOLID FORMS OF BENDAMUSTINE CHLORHYDRATE
US11730407B2 (en) 2008-03-28 2023-08-22 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US8583204B2 (en) 2008-03-28 2013-11-12 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US8682408B2 (en) 2008-03-28 2014-03-25 Dexcom, Inc. Polymer membranes for continuous analyte sensors
DE102008027133A1 (en) * 2008-05-30 2009-12-03 Ls Medcap Gmbh Fully synthetic albumin analog
DE102008002471A1 (en) * 2008-06-17 2009-12-24 Biotronik Vi Patent Ag Stent with a coating or a base body containing a lithium salt, and use of lithium salts for restenosis prophylaxis
US8632605B2 (en) 2008-09-12 2014-01-21 Pneumrx, Inc. Elongated lung volume reduction devices, methods, and systems
GB0816783D0 (en) * 2008-09-15 2008-10-22 Carmeda Ab Immobilised biological entities
WO2010033724A2 (en) 2008-09-19 2010-03-25 Dexcom, Inc. Particle-containing membrane and particulate electrode for analyte sensors
AU2009296734B2 (en) 2008-09-25 2016-02-18 Cephalon Llc Liquid formulations of bendamustine
AU2010204765A1 (en) * 2009-01-15 2011-07-28 Cephalon, Inc. Novel forms of bendamustine free base
WO2010101072A1 (en) * 2009-03-02 2010-09-10 株式会社日本ステントテクノロジー Drug releasing stent
US20110301697A1 (en) * 2009-04-10 2011-12-08 Hemoteq Ag Manufacture, method and use of drug-eluting medical devices for permanently keeping blood vessels open
EP2419435A2 (en) * 2009-04-15 2012-02-22 Basf Se Method for producing monoethylenically unsaturated glycosylamines
EP2421571A2 (en) * 2009-04-24 2012-02-29 Boston Scientific Scimed, Inc. Use of drug polymorphs to achieve controlled drug delivery from a coated medical device
HUE032005T2 (en) * 2009-05-15 2017-08-28 Interface Biologics Inc Antithrombogenic hollow fiber membranes, potting material and blood tubing
JP5809621B2 (en) 2009-05-18 2015-11-11 ヌームアールエックス・インコーポレーテッド Implants for treating a patient's lungs
EP2944332B1 (en) 2009-07-10 2016-08-17 Boston Scientific Scimed, Inc. Use of nanocrystals for a drug delivery balloon
US10080821B2 (en) 2009-07-17 2018-09-25 Boston Scientific Scimed, Inc. Nucleation of drug delivery balloons to provide improved crystal size and density
US8591932B2 (en) * 2009-09-17 2013-11-26 W. L. Gore & Associates, Inc. Heparin entities and methods of use
US8900603B2 (en) 2009-12-18 2014-12-02 Interface Biologics, Inc. Local delivery of drugs from self assembled coatings
US20130197325A1 (en) * 2010-03-03 2013-08-01 Edwards Lifesciences Corporation Anti-coagulant infusion fluid source
GB201004101D0 (en) * 2010-03-12 2010-04-28 Carmeda Ab Immobilised biological entities
CA2794630A1 (en) * 2010-05-14 2011-11-17 Liliana Atanasoska Endoprosthesis
EP2409766A1 (en) * 2010-07-23 2012-01-25 F. Hoffmann-La Roche AG Method for hydrophilising surfaces of fluid components and objects containing such components
WO2012028310A2 (en) * 2010-08-31 2012-03-08 Avidal Vascular Gmbh Pharmaceutical compositions comprising a taxane
EP2611476B1 (en) 2010-09-02 2016-08-10 Boston Scientific Scimed, Inc. Coating process for drug delivery balloons using heat-induced rewrap memory
JP6034795B2 (en) * 2010-12-04 2016-11-30 アレクサンダー リュベンＡｌｅｘａｎｄｅｒ Ｒｕｅｂｂｅｎ COATING FOR COATING BALLOON OF BALLOON CATHETER AND COATING METHOD
US10064406B2 (en) * 2011-01-06 2018-09-04 Cytosorbents Corporation Polymeric sorbent for removal of impurities from whole blood and blood products
EP2667805B1 (en) 2011-01-28 2023-04-05 The General Hospital Corporation Apparatus and method for tissue biopsy
WO2012103492A1 (en) 2011-01-28 2012-08-02 The General Hospital Corporation Method and apparatus for skin resurfacing
EP2508198B1 (en) 2011-04-07 2014-08-27 Fresenius Medical Care Deutschland GmbH Peptides for suppressing inflammation reactions in hemodialysis
ES2518493T3 (en) 2011-04-07 2014-11-05 Fresenius Medical Care Deutschland Gmbh Melanocyte stimulating hormone to suppress inflammatory reactions in hemodialysis
TW201311774A (en) * 2011-06-23 2013-03-16 Toray Industries Hydrophobic polymer compound having anticoagulant activity
WO2013013196A1 (en) 2011-07-21 2013-01-24 The General Hospital Corporation Method and apparatus for damage and removal of fat
US8669360B2 (en) 2011-08-05 2014-03-11 Boston Scientific Scimed, Inc. Methods of converting amorphous drug substance into crystalline form
WO2013028208A1 (en) 2011-08-25 2013-02-28 Boston Scientific Scimed, Inc. Medical device with crystalline drug coating
RU2484178C2 (en) * 2011-09-08 2013-06-10 Федеральное Государственное Бюджетное Учреждение Науки Институт Биохимической Физики Им. Н.М. Эмануэля Российской Академии Наук (Ибхф Ран) Method of producing protein coatings on surface of solid bodies containing mixed valence metal ions
US8669314B2 (en) 2012-02-03 2014-03-11 Sabic Innovative Plastics Ip B.V. Hydrolytic stability in polycarbonate compositions
CN104168927B (en) * 2012-03-27 2016-10-05 泰尔茂株式会社 Coating composition and medical apparatus and instruments
US20130303983A1 (en) * 2012-05-09 2013-11-14 Cook Medical Technologies Llc Coated medical devices including a water-insoluble therapeutic agent
CN102691083B (en) * 2012-05-29 2014-12-03 上海大学 Electrochemical method for improving blood compatibility of surface of metal material
DE102012010800A1 (en) * 2012-06-01 2013-12-05 Alexander Rübben Coating of balloon catheters
US9395468B2 (en) 2012-08-27 2016-07-19 Ocular Dynamics, Llc Contact lens with a hydrophilic layer
WO2014112956A1 (en) 2013-01-17 2014-07-24 Center Odličnosti Polimerni Marteriali In Tehnologije Method for treatment of a vascular graft
US10543127B2 (en) 2013-02-20 2020-01-28 Cytrellis Biosystems, Inc. Methods and devices for skin tightening
CN105263536B (en) * 2013-03-15 2017-10-31 巴克斯特国际公司 Fixation of the activating agent on substrate
AU2014274766B2 (en) 2013-06-07 2017-12-07 Baxter Healthcare Sa Immobilization of an active agent on a substrate using compounds including trihydroxyphenyl groups
EP3060174B1 (en) * 2013-10-22 2020-05-27 Concievalve LLC Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis
CA2930552C (en) 2013-11-15 2022-12-13 Ocular Dynamics, Llc Contact lens with a hydrophilic layer
IL229645A0 (en) * 2013-11-26 2014-03-31 Omrix Biopharmaceuticals Ltd Dry pad comprising thrombin and pectin
CN103721300B (en) * 2013-12-19 2015-05-20 华中科技大学 Anticoagulation coating material and preparation method thereof
US11839698B2 (en) 2014-03-13 2023-12-12 W. L. Gore & Associates, Inc. Drug composition and coating
US10390838B1 (en) 2014-08-20 2019-08-27 Pneumrx, Inc. Tuned strength chronic obstructive pulmonary disease treatment
JP6389009B2 (en) * 2014-10-30 2018-09-12 チェンデュ バイユ ファーマシューティカル カンパニー リミテッドＣｈｅｎｇｄｕ Ｂａｉｙｕ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．，Ｌｔｄ． Drug composition containing ginkgolide B and factor Xa inhibitor, method for producing the same, and use thereof
WO2016077759A1 (en) 2014-11-14 2016-05-19 Cytrellis Biosystems, Inc. Devices and methods for ablation of the skin
CN107206119B (en) * 2014-12-09 2021-01-29 实体科学公司 Medical device coating with biocompatible layer
US20170145475A1 (en) 2015-11-20 2017-05-25 Streck, Inc. Single spin process for blood plasma separation and plasma composition including preservative
KR102561605B1 (en) 2016-03-29 2023-08-01 사이트렐리스 바이오시스템즈, 인크. Device and method for cosmetic skin resurfacing
CN106119820B (en) 2016-06-01 2018-06-22 华南理工大学 A kind of method that material surface blood compatibility is improved using controllable crosslinking technology
EP3258260B1 (en) 2016-06-16 2020-01-15 Lake Region Manufacturing, Inc. Composite column for use in high pressure liquid chromatography
US11464954B2 (en) 2016-09-21 2022-10-11 Cytrellis Biosystems, Inc. Devices and methods for cosmetic skin resurfacing
CA3041063C (en) 2016-10-18 2021-06-08 Interface Biologics, Inc. Plasticized pvc admixtures with surface modifying macromolecules and articles made therefrom
IT201700075956A1 (en) * 2017-07-12 2019-01-12 Mediplasma S R L Covalent immobilization of heparin on contact lenses (LAC) and devices of medical-surgical interest treated via plasma
CN110891997B (en) 2017-07-14 2022-05-24 费森尤斯医疗保健控股公司 Method for providing surface modification compositions with improved byproduct removal
CN107456611A (en) * 2017-07-23 2017-12-12 北京化工大学 A kind of preparation method of anticoagulation composite coating
WO2019079743A1 (en) * 2017-10-19 2019-04-25 Streck, Inc. Compositions for hemolysis and coagulation regulation and stabilization of extracellular vesicles
CN109925536B (en) * 2017-12-15 2021-01-26 先健科技(深圳)有限公司 Absorbable iron-based implantable device
EP3796948A4 (en) 2018-05-22 2022-03-02 Interface Biologics Inc. Compositions and methods for delivering drugs to a vessel wall
CN108715875B (en) * 2018-05-30 2021-05-25 上海交通大学 Method for synthesizing heparin sulfate oligosaccharide with definite structure by enzyme chemistry method
CN112169018A (en) * 2018-09-25 2021-01-05 湖南博隽生物医药有限公司 Antithrombotic heart valve replacement
CN109568676A (en) * 2018-12-29 2019-04-05 张桂玲 A kind of antibacterial super slippery medical retention conduit material
CN109821076B (en) * 2019-03-13 2021-05-07 陕西师范大学 Preparation method of multifunctional anticoagulant and anti-infection coating and multifunctional anticoagulant and anti-infection material
US11931482B2 (en) 2019-03-18 2024-03-19 Brown University Auranofin-releasing antibacterial and antibiofilm polyurethane intravascular catheter coatings
CN109806850B (en) * 2019-03-25 2021-12-10 东华大学 Viscose non-woven fabric material with adsorption performance and preparation method thereof
CN109943068B (en) * 2019-03-28 2022-01-25 金旸（厦门）新材料科技有限公司 High-temperature-resistant nylon material, electroplating nylon material, preparation method and application thereof
CN110506634B (en) * 2019-09-29 2022-07-05 上海市农业科学院 Iris chemical mutagenesis dose screening method
TWI749395B (en) * 2019-11-08 2021-12-11 高鼎精密材料股份有限公司 Method for fabricating polymer fiber tubular structure with high patency rate
CN110790970B (en) * 2019-11-22 2022-08-12 辽宁万鑫富利新材料有限公司 Preparation method of PET (polyethylene terephthalate) composite film material with high blood compatibility
BR112022010381A2 (en) * 2019-11-30 2022-09-13 Smart Reactors Service Ltd COATING FOR MEDICAL DEVICES
CN111729083B (en) * 2020-04-03 2022-08-23 广州医科大学附属第二医院 Novel use of endothelin C receptor
CN111644084A (en) * 2020-06-15 2020-09-11 齐松松 Modified carboxymethyl chitosan polytetrafluoroethylene nanofiltration membrane and preparation method thereof
CN113171499A (en) * 2021-03-17 2021-07-27 广东粤港澳大湾区国家纳米科技创新研究院 Anticoagulation material, double-layer hydrogel pipeline, and preparation method and application thereof
CN115607750B (en) * 2021-07-16 2024-02-23 中国科学院宁波材料技术与工程研究所 In-situ anticoagulation modified medical PVC material, and preparation method and application thereof
CN113616861A (en) * 2021-08-03 2021-11-09 广州维力医疗器械股份有限公司 Layer-by-layer self-assembly composite anticoagulant coating, preparation method thereof and medical instrument
CN113648013A (en) * 2021-08-25 2021-11-16 心凯诺医疗科技(上海)有限公司 Close net support of blood flow direction
CN114949347B (en) * 2022-05-31 2023-05-12 四川大学 Modified crosslinked biological valve and preparation method and application thereof
CN115490827A (en) * 2022-11-16 2022-12-20 北京新尖科技有限公司 Polycarbonate polydimethylsiloxane type polyurethane urea and preparation method thereof
CN117696017A (en) * 2024-02-05 2024-03-15 四川大学华西医院 Blood purification adsorption modified material and preparation method thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4152513A (en) * 1977-06-01 1979-05-01 University Of Delaware Preparation of alkyl glycosides of amino sugars
DE2862107D1 (en) * 1977-12-02 1982-11-18 Takeda Chemical Industries Ltd Glucosamine-peptide derivatives and their pharmaceutical compositions
JPS56161803A (en) 1980-05-17 1981-12-12 Nitto Electric Ind Co Ltd Treatment of resin containing organic solution
US4572901A (en) * 1983-06-23 1986-02-25 Children's Hospital Medical Center Of Northern California Method and composition for protein immobilization
US4661345A (en) * 1985-02-26 1987-04-28 The Rockefeller University Method for treating pertussis
SE8501613D0 (en) 1985-04-01 1985-04-01 Bio Carb Ab ASSOCIATIONS FOR THERAPEUTIC OR DIAGNOSTIC APPLICATION WITHOUT PROCEDURES FOR THERAPEUTIC TREATMENT
US5155110A (en) * 1987-10-27 1992-10-13 Warner-Lambert Company Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition
US5206318A (en) * 1989-04-20 1993-04-27 Mitsui Toatsu Chemicals, Inc. Styrene derivatives having N-acetylchito-oligosaccharide chains and method for the same
US5510077A (en) * 1992-03-19 1996-04-23 Dinh; Thomas Q. Method of making an intraluminal stent
US5583121A (en) * 1994-01-12 1996-12-10 Michigan State University Non-anticoagulant chemically modified heparinoids for treating hypovolemic shock and related shock syndromes
EP0769502B1 (en) * 1994-07-01 2003-10-15 Seikagaku Corporation Process for producing desulfated polysaccharide and desulfated heparin
US6179817B1 (en) * 1995-02-22 2001-01-30 Boston Scientific Corporation Hybrid coating for medical devices
US5718862A (en) * 1996-04-24 1998-02-17 Hercules Incorporated Secondary shaping of ionically crosslinked polymer compositions for medical devices
US5767269A (en) * 1996-10-01 1998-06-16 Hamilton Civic Hospitals Research Development Inc. Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics
US5997517A (en) * 1997-01-27 1999-12-07 Sts Biopolymers, Inc. Bonding layers for medical device surface coatings
DE19705366C2 (en) * 1997-02-12 2002-08-01 Fresenius Ag Carrier material for cleaning protein-containing solutions, method for producing the carrier material and use of the carrier material
DE19724869C2 (en) 1997-06-12 1999-05-12 Henkel Kgaa Use of citosan derivatives for surface coating
US6306166B1 (en) * 1997-08-13 2001-10-23 Scimed Life Systems, Inc. Loading and release of water-insoluble drugs
FI974321A0 (en) * 1997-11-25 1997-11-25 Jenny Ja Antti Wihurin Rahasto Multiple heparinglycosaminoglycans and proteoglycans are used
IT1296581B1 (en) * 1997-11-28 1999-07-14 Istituto Scient Di Chimica E B NON THROMBOGENIC POLYMERIC MATERIALS AND EXCELLENT COMPATIBILITY WITH ORGANIC FLUIDS AND TISSUES
US5922692A (en) * 1998-03-11 1999-07-13 Marino; Richard P. Concentration of glycosaminoglycans and precursors thereto in food products
US6206914B1 (en) * 1998-04-30 2001-03-27 Medtronic, Inc. Implantable system with drug-eluting cells for on-demand local drug delivery
DE69935716T2 (en) * 1998-05-05 2007-08-16 Boston Scientific Ltd., St. Michael STENT WITH SMOOTH ENDS
ITPD980169A1 (en) * 1998-07-06 2000-01-06 Fidia Advanced Biopolymers Srl AMIDES OF HYALURONIC ACID AND ITS DERIVATIVES AND PROCESS FOR THEIR PREPARATION.
US6299604B1 (en) * 1998-08-20 2001-10-09 Cook Incorporated Coated implantable medical device
ATE464947T1 (en) * 1999-01-22 2010-05-15 Dow Global Technologies Inc SURFACE MODIFIED DIVINYLBENZENE RESIN WITH HEMOCOMPATIBLE COATING
DE19908318A1 (en) 1999-02-26 2000-08-31 Michael Hoffmann Hemocompatible surfaces and methods of making them
US6258121B1 (en) * 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
US7781416B2 (en) * 2000-01-25 2010-08-24 Sigma-Tau Research Switzerland S.A. Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
EP1278559B1 (en) * 2000-04-28 2008-03-26 Baylor College Of Medicine Decellularised vascular prostheses
US6489311B1 (en) * 2000-05-02 2002-12-03 Charlotte-Mecklenburg Hospital Authoirty Method for the prevention of apoptosis
NO20013534L (en) * 2000-07-18 2002-01-21 Koyo Chemical Company Ltd Use of a composition comprising a glucosamine salt or a glucosamine derivative for the manufacture of a medicament for the treatment of human thrombosis
US6503538B1 (en) * 2000-08-30 2003-01-07 Cornell Research Foundation, Inc. Elastomeric functional biodegradable copolyester amides and copolyester urethanes
US20020087123A1 (en) * 2001-01-02 2002-07-04 Hossainy Syed F.A. Adhesion of heparin-containing coatings to blood-contacting surfaces of medical devices
US6833488B2 (en) * 2001-03-30 2004-12-21 Exotech Bio Solution Ltd. Biocompatible, biodegradable, water-absorbent material and methods for its preparation
CA2458828A1 (en) * 2001-09-24 2003-05-01 James J. Barry Optimized dosing for drug coated stents
DK1435877T3 (en) * 2001-10-15 2009-08-03 Hemoteq Ag Coating of stents to prevent restenosis
WO2003094991A1 (en) * 2002-05-09 2003-11-20 Hemoteq Gmbh Medical products comprising a haemocompatible coating, production and use thereof

Also Published As

Publication number Publication date
JP5106750B2 (en) 2012-12-26
AU2003240391B2 (en) 2007-05-17
BR0310008A (en) 2005-02-15
US20050176678A1 (en) 2005-08-11
PT1501565E (en) 2007-02-28
EP1501566B1 (en) 2008-08-13
JP2010189649A (en) 2010-09-02
CN1543362A (en) 2004-11-03
AU2003243885B2 (en) 2007-05-24
PL373225A1 (en) 2005-08-22
JP2005528149A (en) 2005-09-22
EP1501566A1 (en) 2005-02-02
JP4208830B2 (en) 2009-01-14
US20110009955A1 (en) 2011-01-13
EA200401485A1 (en) 2005-06-30
CA2484269C (en) 2012-01-17
PT1501566E (en) 2008-11-13
PL373226A1 (en) 2005-08-22
EP1501565A1 (en) 2005-02-02
CA2484374C (en) 2011-05-17
CN1665554A (en) 2005-09-07
IL164947A0 (en) 2005-12-18
DE50305580D1 (en) 2006-12-14
WO2003094991A1 (en) 2003-11-20
ZA200408757B (en) 2005-07-27
CN1318103C (en) 2007-05-30
ATE404232T1 (en) 2008-08-15
DE10393060D2 (en) 2005-05-04
ZA200408791B (en) 2005-07-27
MXPA04011111A (en) 2005-07-14
DK1501565T3 (en) 2007-03-19
DE50310322D1 (en) 2008-09-25
ATE344064T1 (en) 2006-11-15
AU2003240391A1 (en) 2003-11-11
DE10393059D2 (en) 2005-05-04
PL208277B1 (en) 2011-04-29
ES2321082T3 (en) 2009-06-02
NZ536331A (en) 2007-08-31
JP2005534724A (en) 2005-11-17
CA2484269A1 (en) 2003-11-20
WO2003094990A1 (en) 2003-11-20
PL208115B1 (en) 2011-03-31
NZ536330A (en) 2007-08-31
AU2003243885A1 (en) 2003-11-11
CN1665554B (en) 2011-05-18
US20040234575A1 (en) 2004-11-25
IL164948A0 (en) 2005-12-18
AU2003240391B8 (en) 2009-08-06
EP1501565B1 (en) 2006-11-02
BR0311446A (en) 2005-03-15
MXPA04011112A (en) 2005-07-14
AU2003243885B8 (en) 2009-08-06
US8784862B2 (en) 2014-07-22
DK1501566T3 (en) 2008-12-15
SI1501566T1 (en) 2008-12-31
IL164947A (en) 2009-06-15
ES2276065T3 (en) 2007-06-16
EA009092B1 (en) 2007-10-26

Similar Documents

Publication Publication Date Title
CA2484374A1 (en) Medical products comprising a haemocompatible coating, production and use thereof
JP5026956B2 (en) Natural biodegradable polysaccharide coating for medical devices
JP4236467B2 (en) Implantable device coating and method for forming the same
AU2001281304B2 (en) Medicament incorporation matrix
JP3421652B2 (en) Coating composition
US7001421B2 (en) Stent with phenoxy primer coating
US20060030669A1 (en) Thermally-reactive polymers
CN101309709A (en) Coatings and articles including natural biodegradable polysaccharides
US20040138695A1 (en) Coatings of implants
WO2005097223A1 (en) Composition and method for preparing biocompatible surfaces
JP2008539832A (en) Coating the entire surface of a vascular stent
JP2007518850A (en) Biobeneficial polyamide / polyethylene glycol polymer for use with drug eluting stents
JP2007530173A (en) Methods and systems for biocompatible surfaces
CA2594030A1 (en) Biodegradable coating compositions including multiple layers
AU2001281304A1 (en) Medicament incorporation matrix
Roina et al. ePTFE functionalization for medical applications
US20040147999A1 (en) Stent with epoxy primer coating
Kyzioł et al. Surface functionalization of biomaterials
CA2286687A1 (en) Collagen-like polymers with cell binding activity
JP5148106B2 (en) Photoactive biocompatible coating composition
Ishihara et al. Bioinspired functionalization of metal surfaces with polymers
Anderson et al. Technologies for the surface modification of biomaterials

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20200831